[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 467
Citations 0
Correction
April 2017

Omitted Sentences in Conclusions and Relevance

JAMA Cardiol. 2017;2(4):461. doi:10.1001/jamacardio.2017.0021

In the Original Investigation by Elam et al titled “Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes,” published online December 28, 2016,1 the first and last sentences of the Conclusions and Relevance section of the Abstract were inadvertently deleted by manuscript editing during the Production process. The section should have read as follows: “Extended follow-up of ACCORD-lipid trial participants confirms the original neutral effect of fenofibrate in the overall study cohort. The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol. A definitive trial of fibrate therapy in this patient population is needed to confirm these findings.”

Additionally, the Meaning section of the Key Points has been expanded and now reads: “Extended follow-up of ACCORD-lipid trial participants confirms the original neutral effect of fenofibrate in the overall study cohort; the continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol.” This article was corrected online.

References
1.
Elam  MB, Ginsberg  HN, Lovato  LC,  et al.  Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes [published online December 28, 2016].  JAMA Cardiol. doi:10.1001/jamacardio.2016.4828
×